Novartis Benefits from Faster China Drug Approvals

by swisschambei in Engineering / Manufacturing

Novartis, the Swiss pharmaceutical company, plans to submit 50 new drug applications in China over the next few years, as it projects faster Chinese drug approvals which could see the country overtake Europe to become its second-largest market. China’s pharmaceutical market is undergoing a shake-up as approvals for new drugs accelerate while the government forces lower prices for off-patent branded drugs which have accounted for most of multinationals’ sales in the country. Novartis expects to submit 50 new drug applications in China by 2023, which will be split roughly evenly between innovative and off-patent drugs, the company’s head of global drug development John Tsai said in an interview. The company has had 24 drugs approved in China in the past two years, most recently the multiple sclerosis treatment Gilenya in June. “We absolutely think China will be the number two market for us,” said Tsai.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Your Swiss Business Platform in China

SwissCham China has roughly 600 company members. Our Chamber maintains a strong relationship with the Embassy of Switzerland, Swiss Global Enterprise, Swissnex and Switzerland Tourism. As the representative of the Swiss companies established in China, our goal is to help you to increase your business and visibility, especially amongst the Sino-Swiss business community.

Become A Member

Sign Up For Our Newsletter

  • This field is for validation purposes and should be left unchanged.
June 4, 2021
Published By swisstrade.com in Bilateral Relations
June 3, 2021
Published By prnewswire.com in Business
May 28, 2021
Published By chinadaily.com.cn in Engineering / Manufacturing
May 20, 2021
Published By globaltimes.cn in Bilateral Relations
May 18, 2021
Published By globaltimes.cn in Culture & Society